Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aims: This European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients.
Methods: Evidence-based review.
Results: Statin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-high-risk patients with mild to moderately elevated TG levels (>2.3 and < 5.6 mmol/L [>200 and < 500 mg/dL) on a statin, treatment with either a fibrate or high-dose omega-3 fatty acids (icosapent ethyl) may be considered, weighing the benefit versus risks. Combination with fenofibrate may be considered for both macro- and microvascular benefits in patients with type 2 diabetes mellitus.
Conclusions: This guidance aims to improve real-world use of guideline-recommended combination lipid modifying treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.atherosclerosis.2021.03.039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: The residual risk of chronic kidney disease (CKD) progression remains high in clinical trials of kidney protective drugs in patients with diabetic kidney disease (DKD).
Methods: In a prospective study, we assessed whether 16 plasma and 10 urine cytokine levels can inform the residual risk of CKD progression in 93 incident patients with DKD treated by Nephrology according to clinical guidelines.
Results: Plasma and urine levels of 12 plasma and 7 urinary cytokines differed between patients with DKD and from healthy controls.
Dengue among immunocompromised patients: a systematic review and meta-analysis.
J Travel Med
September 2025
Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Background: Although there is a rising trend in both dengue cases and immunocompromised conditions, there is limited research on how common severe dengue is in immunocompromised individuals. This data is key for those advising the ever-increasing numbers of immunocompromised travellers.
Methods: We conducted a systematic review and meta-analysis of studies reporting dengue frequency or outcomes in immunocompromised populations.
Machine Learning Prediction of Cardiovascular Risk in Type 1 Diabetes Mellitus Using Radiomic Features from Multimodal Retinal Images.
Ophthalmol Sci
July 2025
Institut Clínic d'Oftalmología (ICOF), Hospital Clínic de Barcelona, Barcelona, Spain.
Purpose: To develop a machine learning (ML) algorithm capable of determining cardiovascular (CV) risk in multimodal retinal images from patients with type 1 diabetes mellitus (T1DM), distinguishing between moderate, high, and very high-risk levels.
Design: Cross-sectional analysis of a retinal image data set from a previous prospective OCT angiography (OCTA) study (ClinicalTrials.gov NCT03422965).
Nocturnal hypoxemic burden is associated with worsening prognosis of chronic kidney disease in patients with type 2 diabetes.
Cardiovasc Diabetol
August 2025
Department of Internal Medicine II, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Germany.
Introduction: Lower estimated glomerular filtration rate (eGFR) and more severe albuminuria categories are associated with increased risk for adverse outcomes such as mortality, cardiovascular and kidney outcomes. The aim of the analysis was to evaluate whether nocturnal hypoxemic burden (NHB) is associated with worsening prognosis of CKD in a population with T2D.
Methods: Overnight oximetry data from patients enrolled in the DIACORE (DIAbetes COhoRtE) sleep-disordered breathing sub-study, a prospective cohort study of patients with T2D, was analyzed and NHB as cumulative time spent below 90% oxygen saturation (T90) was quantified.
The effect of U2AF1 mutation on erythroid differentiation and sensitivity to demethylation drug treatment.
Med Oncol
August 2025
Beijing Key Laboratory of Gene Resource and Molecular Development, Beijing Normal University, Beijing, China.
Myelodysplastic syndrome (MDS) is a group of blood disorders characterized by impaired maturation of erythroid cells. Mutations in the U2 small nuclear RNA auxiliary factor 1 (U2AF1) gene, particularly S34 (S34F/Y) and Q157 (Q157P/R), have been identified in 5-10% of MDS patients. By analyzing U2AF1 expression in hematopoietic stem progenitor cells and different blood cells in the GEO database, we have found the expression pattern of U2AF1 showed a significant stage specificity during normal erythropoiesis.
View Article and Find Full Text PDF